Molecular Pharmacology and Physiology
USF Health � College of Medicine
Login here to update your profile  
My Profile

Marcia Gordon , Ph.D.

Primary Department: COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

Professor
COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY
profile Image
Contacts
Email: mgordon@health.usf.edu
Phone: (813) 974-9926
Office: ALZ, 443
Mailing address USF Health Byrd Alzheimer's Institute ,4001 E. Fletcher Ave.
Tampa, FL 33613
View My C.V.
 
Education
  • PHD, Molecular Biology, University Of Southern California , Los Angeles, CA, United States - 1985.
    		•
  • B.S., Psychobiology, University of Southern California ,USA - 1978.
    		•
     
    Interdisciplinary & Emerging Signature Programs
    Neuroscience.
     
    Research Summary

    * Experimental therapeutics for Alzheimer's disease using animal models
    * Role of glial cells and neuroinflammation in neurodegeneration
    * Development of neuroprotective therapeutics

     


    Selected Publications
  • Gordon, MN.Finch, CE. Topochemical localization of choline acetyltransferase and acetylcholinesterase in mouse brain. Brain research. 308(2): 364-8, 1984.
  • Gordon, MN.Mobbs, CV.Finch, CE. The antiestrogen LY117018 blocks effects of estradiol on pituitary glucose-6-phosphate dehydrogenase specific activity and on serum LH. Neuroendocrinology. 40(5): 381-4, 1985.
  • Gordon, MN.Osterburg, HH.May, PC.Finch, CE. Effective oral administration of 17 beta-estradiol to female C57BL/6J mice through the drinking water. Biology of reproduction. 35(5): 1088-95, 1986.
  • Morgan, DG.Marcusson, JO.Nyberg, P.Wester, P.Winblad, B.Gordon, MN.Finch, CE. Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. Neurobiology of aging. 8(3): 195-201, 1987.
  • McGurk, SR.Hartgraves, SL.Kelly, PH.Gordon, MN.Butcher, LL. Is ethylcholine mustard aziridinium ion a specific cholinergic neurotoxin? Neuroscience. 22(1): 215-24, 1987.
  • Morgan, DG.Randall, JS.Telford, NA.Gordon, MN.Sinha, YN.Finch, CE.Randall, PK. Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology. 12(3): 211-8, 1987.
  • Gordon, MN.Schechter, JE.Felicio, LS.Finch, CE. Spontaneous tumors in aging female mice are more prevalent in the lateral pituitary zones. Neurobiology of aging. 8(1): 67-70, 1987.
  • Morgan, DG.Gordon, MN. New approaches to the study of central nervous system function. Immune-nervous system interactions and cell culture. Neurobiology of aging. 9(5-6): 763-5, 1988.
  • Gordon, MN.Mobbs, CV.Finch, CE. Pituitary and hypothalamic glucose-6-phosphate dehydrogenase: effects of estradiol and age in C57BL/6J mice. Endocrinology. 122(2): 726-33, 1988.
  • Kumar, S.Gordon, MN.Espinosa de los Monteros, MA.de Vellis, J. Developmental expression of neural cell type-specific mRNA markers in the myelin-deficient mutant rat brain: inhibition of oligodendrocyte differentiation. Journal of neuroscience research. 21(2-4): 268-74, 1988.
  • Gordon, MN.Kumar, S.Espinosa de los Monteros, A.Scully, S.Zhang, MS.Huber, J.Cole, RA.de Vellis, J. Developmental regulation of myelin-associated genes in the normal and the myelin deficient mutant rat. Advances in experimental medicine and biology. 265(): 11-22, 1990.
  • Espinosa de los Monteros, A.Zhang, M.Gordon, MN.Kumar, S.Scully, SA.de Vellis, J. The myelin-deficient rat mutant: partial recovery of oligodendrocyte maturation in vitro. Developmental neuroscience. 12(4-5): 326-39, 1990.
  • Kumar, S.Macklin, WB.Gordon, MN.Espinosa de los Monteros, A.Cole, R.Scully, SA.de Vellis, J. Transcriptional regulation studies of myelin-associated genes in myelin-deficient mutant rats. Developmental neuroscience. 12(4-5): 316-25, 1990.
  • Espinosa de los Monteros, A.Zhang, MS.Gordon, M.Aymie, M.de Vellis, J. Transplantation of cultured premyelinating oligodendrocytes into normal and myelin-deficient rat brain. Developmental neuroscience. 14(2): 98-104, 1992.
  • Gordon, MN.Kumar, S.Espinosa de los Monteros, A.de Vellis, J. Ontogeny of glycerol phosphate dehydrogenase-positive oligodendrocytes in rat brain. Impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 10(4): 243-53, 1992.
  • Pasinetti, GM.Johnson, SA.Rozovsky, I.Lampert-Etchells, M.Morgan, DG.Gordon, MN.Morgan, TE.Willoughby, D.Finch, CE. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Experimental neurology. 118(2): 117-25, 1992.
  • Gordon, MN. Microglia and immune activation in Alzheimer's disease. The Journal of the Florida Medical Association. 80(4): 267-70, 1993.
  • Duff, K.Eckman, C.Zehr, C.Yu, X.Prada, CM.Perez-tur, J.Hutton, M.Buee, L.Harigaya, Y.Yager, D.Morgan, D.Gordon, MN.Holcomb, L.Refolo, L.Zenk, B.Hardy, J.Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383(6602): 710-3, 1996.
  • Gordon, MN.Schreier, WA.Ou, X.Holcomb, LA.Morgan, DG. Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. The Journal of comparative neurology. 388(1): 106-19, 1997.
  • Benkovic, SA.McGowan, EM.Rothwell, NJ.Hutton, M.Morgan, DG.Gordon, MN. Regional and cellular localization of presenilin-2 RNA in rat and human brain. Experimental neurology. 145(2 Pt 1): 555-64, 1997.
  • Holcomb, L.Gordon, MN.McGowan, E.Yu, X.Benkovic, S.Jantzen, P.Wright, K.Saad, I.Mueller, R.Morgan, D.Sanders, S.Zehr, C.O'Campo, K.Hardy, J.Prada, CM.Eckman, C.Younkin, S.Hsiao, K.Duff, K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature medicine. 4(1): 97-100, 1998.
  • Morgan, D.Holcomb, L.Saad, I.Gordon, M.Mahin Maines. Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain research. 808(1): 110-2, 1998.
  • Gordon, MN.Muller, CD.Sherman, KA.Morgan, DG.Azzaro, AJ.Wecker, L. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacology, biochemistry, and behavior. 63(3): 501-6, 1999.
  • Duckworth EA, Koutouzis TD, Borlongan CV, Gordon MN, Willing AE, Cahill DW, Sanberg PR Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze Psychobiology. 27(): 561-566, 1999.
  • Wright, KL.Morgan, DG.Yu, X.Goss, JR.Salbaum, JM.Duff, K.Gordon, MN. Mice transgenic for a human amyloid precursor protein promoter-lacZ reporter construct. Journal of molecular neuroscience : MN. 13(1-2): 111-20, 1999.
  • Holcomb, LA.Gordon, MN.Jantzen, P.Hsiao, K.Duff, K.Morgan, D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behavior genetics. 29(3): 177-85, 1999.
  • Holcomb, LA.Gordon, MN.Benkovic, SA.Morgan, DG. A beta and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity. Mechanisms of ageing and development. 112(2): 135-52, 2000.
  • Morgan, D.Diamond, DM.Gottschall, PE.Ugen, KE.Dickey, C.Hardy, J.Duff, K.Jantzen, P.DiCarlo, G.Wilcock, D.Connor, K.Hatcher, J.Hope, C.Gordon, M.Arendash, GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408( ): 982-5, 2000.
  • Pennypacker, KR.Yang, X.Gordon, MN.Benkovic, S.Miller, D.O'Callaghan, JP. Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine- and trimethyltin-induced brain injury. Neuroscience. 101(4): 913-9, 2000.
  • Arendash, GW.King, DL.Gordon, MN.Morgan, D.Hatcher, JM.Hope, CE.Diamond, DM. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain research. 891(1-2): 42-53, 2001.
  • Nilsson, LN.Bales, KR.DiCarlo, G.Gordon, MN.Morgan, D.Paul, SM.Potter, H. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 21(5): 1444-51, 2001.
  • Gordon, MN.King, DL.Diamond, DM.Jantzen, PT.Boyett, KV.Hope, CE.Hatcher, JM.DiCarlo, G.Gottschall, WP.Morgan, D.Arendash, GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of aging. 22(3): 377-85, 2001.
  • Jaffar, S.Counts, SE.Ma, SY.Dadko, E.Gordon, MN.Morgan, D.Mufson, EJ. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Experimental neurology. 170(2): 227-43, 2001.
  • Dickey, CA.Morgan, DG.Kudchodkar, S.Weiner, DB.Bai, Y.Cao, C.Gordon, MN.Ugen, KE. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA and cell biology. 20(11): 723-9, 2001.
  • Wilcock, DM.Gordon, MN.Ugen, KE.Gottschall, PE.DiCarlo, G.Dickey, C.Boyett, KW.Jantzen, PT.Connor, KE.Melachrino, J.Hardy, J.Morgan, D. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA and cell biology. 20(11): 731-6, 2001.
  • Arendash, GW.Gordon, MN.Diamond, DM.Austin, LA.Hatcher, JM.Jantzen, P.DiCarlo, G.Wilcock, D.Morgan, D. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA and cell biology. 20(11): 737-44, 2001.
  • DiCarlo, G.Wilcock, D.Henderson, D.Gordon, M.Morgan, D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiology of aging. 22(6): 1007-12, 2001.
  • Jantzen, PT.Connor, KE.DiCarlo, G.Wenk, GL.Wallace, JL.Rojiani, AM.Coppola, D.Morgan, D.Gordon, MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(6): 2246-54, 2002.
  • Gordon, MN.Holcomb, LA.Jantzen, PT.DiCarlo, G.Wilcock, D.Boyett, KW.Connor, K.Melachrino, J.O'Callaghan, JP.Morgan, D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental neurology. 173(2): 183-95, 2002.
  • Boyett, KW.DiCarlo, G.Jantzen, PT.Jackson, J.O'Leary, C.Wilcock, D.Morgan, D.Gordon, MN. Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical research. 28(1): 83-93, 2003.
  • Dickey, CA.Loring, JF.Montgomery, J.Gordon, MN.Eastman, PS.Morgan, D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(12): 5219-26, 2003.
  • Joseph, JA.Denisova, NA.Arendash, G.Gordon, M.Diamond, D.Shukitt-Hale, B.Morgan, D. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutritional neuroscience. 6(3): 153-62, 2003.
  • Austin, L.Arendash, GW.Gordon, MN.Diamond, DM.DiCarlo, G.Dickey, C.Ugen, K.Morgan, D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behavioral neuroscience. 117(3): 478-84, 2003.
  • Kassed, CA.Butler, TL.Navidomskis, MT.Gordon, MN.Morgan, D.Pennypacker, KR. Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury. Brain research. Molecular brain research. 110(1): 152-7, 2003.
  • Wilcock, DM.DiCarlo, G.Henderson, D.Jackson, J.Clarke, K.Ugen, KE.Gordon, MN.Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(9): 3745-51, 2003.
  • Chaudhury, AR.Gerecke, KM.Wyss, JM.Morgan, DG.Gordon, MN.Carroll, SL. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. Journal of neuropathology and experimental neurology. 62(1): 42-54, 2003.
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Levkowitz, G.Subbarao, S.Alamed, J.Wilson, D.Wilson, N.Freeman, MJ.Gordon, MN.Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24(27): 6144-51, 2004.
  • Garcia, MF.Gordon, MN.Hutton, M.Lewis, J.McGowan, E.Dickey, CA.Morgan, D.Arendash, GW. The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport. 15(1): 73-7, 2004.
  • Zhang, J.Yarowsky, P.Gordon, MN.Di Carlo, G.Munireddy, S.van Zijl, PC.Mori, S. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 51(3): 452-7, 2004.
  • Wilcock, DM.Munireddy, SK.Rosenthal, A.Ugen, KE.Gordon, MN.Morgan, D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiology of disease. 15(1): 11-20, 2004.
  • Dickey, CA.Gordon, MN.Mason, JE.Wilson, NJ.Diamond, DM.Guzowski, JF.Morgan, D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. Journal of neurochemistry. 88(2): 434-42, 2004.
  • Wilcock, DM.Rojiani, A.Rosenthal, A.Subbarao, S.Freeman, MJ.Gordon, MN.Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of neuroinflammation [electronic resource].. 1(1): 24, 2004.
  • Herber, DL.Roth, LM.Wilson, D.Wilson, N.Mason, JE.Morgan, D.Gordon, MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Experimental neurology. 190(1): 245-53, 2004.
  • Herber, DL.Severance, EG.Cuevas, J.Morgan, D.Gordon, MN. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 52(10): 1367-76, 2004.
  • Ambegaonkar MU, Nagle AS, Breitner JC, Deleon J, Alamed J, Wilson N, Morgan D, Gordon MN The histamine H2-receptor antagonist cimetidine activates microglia in APP+PS1 transgenic mice Brain Aging. 4(): 35-40, 2004.
  • Li, Q.Cao, C.Chackerian, B.Schiller, J.Gordon, M.Ugen, KE.Morgan, D. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC neuroscience. 5(): 21, 2004.
  • Dickey, CA.Gordon, MN.Wilcock, DM.Herber, DL.Freeman, MJ.Morgan, D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC neuroscience. 6(1): 7, 2005.
  • Morgan, D.Gordon, MN.Tan, J.Wilcock, D.Rojiani, AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of neuropathology and experimental neurology. 64(9): 743-53, 2005.
  • Patel, NV.Gordon, MN.Connor, KE.Good, RA.Engelman, RW.Mason, J.Morgan, DG.Morgan, TE.Finch, CE. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiology of aging. 26(7): 995-1000, 2005.
  • Ewers, M.Morgan, DG.Gordon, MN.Woodruff-Pak, DS. Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiology of aging. 27(8): 1118-28, 2006.
  • Carty, NC.Wilcock, DM.Rosenthal, A.Grimm, J.Pons, J.Ronan, V.Gottschall, PE.Gordon, MN.Morgan, D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of neuroinflammation. 3(): 11, 2006.
  • Alamed, J.Wilcock, DM.Diamond, DM.Gordon, MN.Morgan, D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nature protocols. 1(4): 1671-9, 2006.
  • Wilcock, DM.Gordon, MN.Morgan, D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature protocols. 1(3): 1591-5, 2006.
  • Herber, DL.Maloney, JL.Roth, LM.Freeman, MJ.Morgan, D.Gordon, MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia. 53(4): 382-91, 2006.
  • Wilcock, DM.Alamed, J.Gottschall, PE.Grimm, J.Rosenthal, A.Pons, J.Ronan, V.Symmonds, K.Gordon, MN.Morgan, D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(20): 5340-6, 2006.
  • Golub, MS.Germann, SL.Mercer, M.Gordon, MN.Morgan, DG.Mayer, LP.Hoyer, PB. Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of aging. (): , 2007.
  • Li, Q.Gordon, M.Cao, C.Ugen, KE.Morgan, D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC neuroscience. 8(): 22, 2007.
  • Wilcock, DM.Jantzen, PT.Li, Q.Morgan, D.Gordon, MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 144(3): 950-60, 2007.
  • Karlnoski, R.Wilcock, D.Dickey, C.Ronan, V.Gordon, MN.Zhang, W.Morgan, D.Taglialatela, G. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of disease. 25(1): 179-88, 2007.
  • Herber, DL.Mercer, M.Roth, LM.Symmonds, K.Maloney, J.Wilson, N.Freeman, MJ.Morgan, D.Gordon, MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2(2): 222-31, 2007.
  • Li, Q.Gordon, M.Etienne, MA.Hammer, RP.Morgan, D. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell transplantation. 17(4): 397-408, 2008.
  • Morgan, D.Munireddy, S.Alamed, J.DeLeon, J.Diamond, DM.Bickford, P.Hutton, M.Lewis, J.McGowan, E.Gordon, MN. Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. Journal of Alzheimer's disease : JAD. 15(4): 605-14, 2008.
  • Carty N, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, Muzyczka N, Gordon MN, Morgan D Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin converting enzyme reduces A-beta deposits in APP+PS1 transgenic mice Molecular Therapy. (): , 2008.
  • Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, Grimm J, Pons J, Morgan D Deglycosylated anti-A-beta antibody dose-response effects on pathology and memory in APP transgenic mice Journal of neuroimmune pharmacology. (): , 2008.
  • Morgan, D.Gordon, MN. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behavioral neuroscience. 122(3): 730-2, 2008.
  • Lord, A.Englund, H.Söderberg, L.Tucker, S.Clausen, F.Hillered, L.Gordon, M.Morgan, D.Lannfelt, L.Pettersson, FE.Nilsson, LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The FEBS journal. 276(4): 995-1006, 2009.
  • Karlnoski, RA.Rosenthal, A.Kobayashi, D.Pons, J.Alamed, J.Mercer, M.Li, Q.Gordon, MN.Gottschall, PE.Morgan, D. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(15): 4964-71, 2009.
  • Li, QY.Gordon, MN.Chackerian, B.Alamed, J.Ugen, KE.Morgan, D. Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 5(1): 133-42, 2010.
  • Ajmo, JM.Bailey, LA.Howell, MD.Cortez, LK.Pennypacker, KR.Mehta, HN.Morgan, D.Gordon, MN.Gottschall, PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. Journal of neurochemistry. 113(3): 784-95, 2010.
  • Lebson, L.Nash, K.Kamath, S.Herber, D.Carty, N.Lee, DC.Li, Q.Szekeres, K.Jinwal, U.Koren, J.Dickey, CA.Gottschall, PE.Morgan, D.Gordon, MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29): 9651-8, 2010.
  • Lee, DC.Rizer, J.Selenica, ML.Reid, P.Kraft, C.Johnson, A.Blair, L.Gordon, MN.Dickey, CA.Morgan, D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of neuroinflammation. 7(): 56, 2010.
  • Carty, N.Lee, D.Dickey, C.Ceballos-Diaz, C.Jansen-West, K.Golde, TE.Gordon, MN.Morgan, D.Nash, K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1): 144-53, 2010.

    • Positions Held
  • Professor (Department of Molecular Pharmacology and Physiology, University of South Florida 2006 - Present)
  • Professor (Department of Pharmacology and Therapeutics, University of South Florida 2005 - 2006)
  • Associate Professor (Department of Pharmacology and Therapeutics, University of South Florida 2000 - 2005)
  • Assistant Professor (Department of Pharmacology and Therapeutics, University of South Florida 1994 - 2000)
  • Visiting Assistant Professor (Department of Pharmacology and Therapeutics, University of South Florida 1992 - 1994)
  • Research Assistant Professor (School of Gerontology, University of Southern California 1989 - 1992)
  • Postgraduate Researcher (Brain Research Institute, University of California, Los Angeles 1985 - 1989)


    • Memberships
  • American Society for Neural Therapy and Repair (Member, 2008 - Present)
  • Society for Neuroscience (member, 1980 - Present)


    • Awards/Honors
  • Silver Performance Award for Outstanding Contributions (University of South Florida Health - 2007)
    		•
  • Travel Award (University of Michigan Claude D. Pepper Geriatrics Research and Training Center - 1992)
    		•
  • Travel Award (American Society of Neurochemistry - 1989)
    		•
  • Postdoctoral Fellowship (Brain Research Institute and Department of Anatomy, University of California at Los Angeles - 1987)
    		•
  • Postdoctoral Fellowship (Mental Retardation Research Center, University of California at Los Angeles - 1985)
    		•
  • Predoctoral Fellowship (Andrus Gerontology Center, University of Southern California - 1982)
    		•
  • Teaching Assistant Fellowship (Department of Biological Sciences, University of Southern California - 1978)
    		•


    Grants
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($286,762.00, 05/01/2008-04/30/2013)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($286,762.00, 05/01/2008-04/30/2013)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($298,337.00, 05/01/2008-04/30/2013)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($301,350.00, 05/01/2008-04/30/2013)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($301,180.00, 05/01/2008-04/30/2013)
  • CELL-BASED THERAPIES USING TRANSGENIC MICE ($60,000.00, 10/01/2007-09/30/2008)
  • CELL-BASED THERAPIES USING TRANSGENIC MICE ($100,000.00, 08/01/2007-05/02/2008)
  • Cell-based therapeutics using transgenic mice ($0.00, 08/01/2007-07/31/2007)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($300,501.00, 06/01/2002-04/30/2007)
  • Transgenic mice, inflammation & the Alzheimer phenotype ($0.00, 05/01/1999-04/30/2007)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($307,733.00, 06/01/2002-04/30/2006)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($307,733.00, 06/01/2002-04/30/2004)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($307,733.00, 06/01/2002-04/30/2004)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($307,733.00, 06/01/2002-04/30/2003)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($93,456.00, 06/01/1999-04/30/2002)
  • TRANSGENIC MICE, INFLAMMATION AND THE ALZHEIMER PHENOTYPE ($164,987.00, 06/01/1999-04/30/2002)


    • Lectures
  • "Monocytes as Gene Therapy Vectors in Models of Alzheimers Disease" University of Texas Health Science Center at San Antonio, Department of Physiology. TX, United States - 2010.
  • "Cellular Foundations of Neuropharmacology I" Neuropharmacology USF. FL, United States - 2010.
  • "Norepinephrine and Epinephrine " Neuropharmacology USF. FL, United States - 2010.
  • "Introduction to Biology and Histology of Neurons and Glia " Graduate Neuroscience USF. FL, United States - 2010.
  • "presented various lectures" Medical Pharmacology; BMS 6400 USF. FL, United States - 2010.
  • "The role of endogenous and blood-derived monocytic cells in Alzheimers disease" Neuroimmunology and Brain Inflammation Satellite Symposium of the Kuopio Alzheimer Symposium. Finland - 2009.
  • "Cellular Foundations of Neuropharmacology I" Neuropharmacology USF. FL, United States - 2009.
  • "Norepinephrine and Epinephrine " Neuropharmacology USF. FL, United States - 2009.
  • "Introduction to Biology and Histology of Neurons and Glia " Graduate Neuroscience USF. FL, United States - 2009.
  • "presented various lectures" Medical Pharmacology; BMS 6400 USF. FL, United States - 2009.
  • "Genetics and Heredity" University of South Florida, Division of Comparative Biomedicine. FL, United States - 2008.
  • "Immunotherapy for Alzheimers Disease" Center for Aging and Brain Repair, University of South Florida. FL, United States - 2008.
  • "Use of monocytes to deliver gene therapy treatment in transgenic mouse models of amyloid deposition" -US International Alzheimers Disease Symposium. FL, United States - 2008.
  • "Cellular Foundations of Neuropharmacology I " Neuropharmacology USF. FL, United States - 2008.
  • "Norepinephrine and Epinephrine " Neuropharmacology USF. FL, United States - 2008.
  • "Introduction to Biology and Histology of Neurons and Glia " Graduate Neuroscience USF. FL, United States - 2008.
  • "presented various lectures" Medical Pharmacology; BMS 6400 USF. FL, United States - 2008.
  • "Use of monocytes to deliver gene therapy treatment in transgenic mouse models of amyloid deposition" USF-Byrd Center Symposium . FL, United States - 2008.
  • "Cytokines, Glia and Neurodegeneration" American Society for Neural Therapy and Repair. FL, United States - 2006.

    • Profile last modified on 01/17/2013